In the present study, both curcumin and Cur@Hb nanocomposites inhibited vascular mimicry and the expressions of VE-cadherin, twist1 and MMP2, suggesting Cur@Hb might be used as an anti-VM drug for hepatoma. Here, GSTM1 is linked to hepatocellular carcinoma.